JNJ
Johnson & Johnson
Set alert
- YTD
- +32.01%
- 1 year
- +44.51%
- Open
- 280.00
- Prev close
- 275.20
- Mkt cap
- 657.68B
- Vol
- 8.97M
- Avg vol
- 6.85M
- EPS
- 6.59
- P/E
- 41.46
- Div yield
- 1.95%
More statistics
- Low
- 273.15
- High
- 282.00
- Forward P/E
- 23.51
- Beta
- 0.21
- Short ratio
- 2.23
- Inst. own
- 76.77%
- Dividend
- 5.36
- Ex-div date
- Nov 23, 2026
- Earnings
- Jan 20, 2027
- 50-d avg
- 265.48
- 200-d avg
- 246.71
- 1y target
- 279.41
Key statistics
- Market cap
- 657.63B
- Enterprise value
- 689.91B
- Trailing P/E
- 41.45
- Forward P/E
- 23.51
- PEG ratio
- 3.10
- Price / sales
- 6.62
- Price / book
- 8.07
- EPS (TTM)
- 6.59
- Beta
- 0.21
- Dividend yield
- 1.95%
- Payout ratio
- 80.12%
- Profit margin
- 16.20%
- Revenue (TTM)
- 99.33B
- Revenue growth
- 5.90%
- Free cash flow
- 18.50B
- Total cash
- 17.23B
- Total debt
- 44.65B
- Return on equity
- 20.02%
- Shares outstanding
- 2.41B
- Short % of float
- 0.78%
- 50-day average
- 265.48
- 200-day average
- 246.71
Analyst view
Consensus: buy
- Target (low)
- 190.00
- Target (mean)
- 279.41
- Target (high)
- 320.00
- Strong buy5
- Buy11
- Hold6
- Sell1
- Strong sell0
Next earnings
Jan 20, 2027
Expected Jan 20, 2027. Consensus EPS estimate 2.92.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 20, 2027 | Dec 27, 2026 | 2.91 | — | — | — |
| Oct 13, 2026 | Sep 27, 2026 | 2.52 | 2.59 | +0.07 | +2.78% |
| Jul 15, 2026 | Jun 28, 2026 | 2.85 | 2.90 | +0.05 | +1.75% |
| Apr 14, 2026 | Mar 29, 2026 | 2.68 | 2.70 | +0.02 | +0.75% |
| Jan 21, 2026 | Dec 28, 2025 | 2.46 | 2.46 | 0.00 | 0.00% |
| Oct 14, 2025 | Sep 28, 2025 | 2.76 | 2.80 | +0.04 | +1.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 15, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 14, 2026 | Leerink Partners | main | Outperform | Outperform |
| Oct 14, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 14, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 7, 2026 | Guggenheim | reit | Buy | Buy |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- jnj.com
News
- Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
- No Tricks, Just Treats: 3 Dividend Stocks With Payouts You Can Trust
- JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4?
- No Tricks, Just Treats: 3 Dividend Stocks With Payouts You Can Trust
- The Big 3: AAPL, JNJ, MMM
- Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
- Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?
- VYM's Price May Be Soaring, but Its Dividend Isn't Keeping Up
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
- Microsoft Goes Jumbo: $25 Billion Bond Sale in the Works
Your note
Sign in to keep a note on JNJ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROADHURST VANESSA | Officer | Sale | Jul 19, 2026 | 23,003 |
| DECKER ROBERT J | Officer | Sale | Feb 26, 2026 | 24,462 |
| DUATO JOAQUIN BOIX | Chief Executive Officer | Sale | Aug 12, 2026 | 307,837 |
| MULHOLLAND KRISTEN | Officer | Conversion of Exercise of derivative security | Feb 12, 2026 | 19,830 |
| REED JOHN C | Officer | Conversion of Exercise of derivative security | Apr 30, 2026 | 24,911 |
| SCHMID TIMOTHY | Officer | Sale | Sep 1, 2026 | 26,251 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.81% | 212,098,264 | 57.94B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 157,226,374 | 42.95B | Jun 29, 2026 |
| State Street Corporation | 5.56% | 133,776,025 | 36.54B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.67% | 64,370,816 | 17.58B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.45% | 59,086,417 | 16.14B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 2.42% | 58,301,609 | 15.93B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 76,421,624 | 20.88B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 62,378,802 | 17.04B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 32,111,390 | 8.77B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 31,247,848 | 8.54B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 29,810,722 | 8.14B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 0.95% | 22,911,023 | 6.26B | Jun 29, 2026 |